RNA Interference of Human α-Synuclein in Mouse

Area of Science:

• Neuroscience
• Molecular Biology
• Gene Therapy

Background:

• Alpha-synuclein (α-synuclein) aggregation is central to Parkinson's disease (PD) pathogenesis.
• Neurodegeneration and cell death in PD are linked to α-synuclein aggregates.

Purpose of the Study:

• To investigate the efficacy of virally mediated RNA interference for reducing human α-synuclein (hSNCA) in vivo.
• To assess the therapeutic potential of targeting hSNCA for Parkinson's disease.

Main Methods:

• Utilized an siRNA design algorithm to identify effective RNA interference sequences with minimal off-targeting.
• Employed adeno-associated virus (AAV) vectors to deliver a specific siRNA (miSyn4) targeting hSNCA into mouse models.
• Administered AAV vectors into the substantia nigra of mice and assessed hSNCA levels and behavioral outcomes.

Main Results:

• The selected siRNA sequence (miSyn4) demonstrated potent hSNCA knockdown in vitro.
• In vivo delivery of AAV-miSyn4 reduced hSNCA levels in the midbrain and cortex of Thy1-hSNCA mice.
• Co-injection of AAV vectors expressing hSNCA and miSyn4 decreased hSNCA expression and rescued associated behavioral deficits.

Conclusions:

• Virally mediated RNA interference is a viable strategy for in vivo knockdown of hSNCA.
• This approach holds promise for developing novel therapies targeting Parkinson's disease by reducing pathogenic hSNCA.